AU727863B2 - Method for generating activated T-cells and antigen-pulsed antigen-presenting cells - Google Patents

Method for generating activated T-cells and antigen-pulsed antigen-presenting cells Download PDF

Info

Publication number
AU727863B2
AU727863B2 AU73712/98A AU7371298A AU727863B2 AU 727863 B2 AU727863 B2 AU 727863B2 AU 73712/98 A AU73712/98 A AU 73712/98A AU 7371298 A AU7371298 A AU 7371298A AU 727863 B2 AU727863 B2 AU 727863B2
Authority
AU
Australia
Prior art keywords
cells
antigen
peptide
cell
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU73712/98A
Other languages
English (en)
Other versions
AU7371298A (en
Inventor
Babita Agrawal
Mark J. Krantz
B. Michael Longenecker
Mark A. Reddish
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seagen Inc
Original Assignee
Biomira Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomira Inc filed Critical Biomira Inc
Publication of AU7371298A publication Critical patent/AU7371298A/en
Application granted granted Critical
Publication of AU727863B2 publication Critical patent/AU727863B2/en
Assigned to ONCOTHYREON INC. reassignment ONCOTHYREON INC. Alteration of Name(s) in Register under S187 Assignors: BIOMIRA INC.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4256—Tumor associated carbohydrates
    • A61K40/4257—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU73712/98A 1997-05-08 1998-05-07 Method for generating activated T-cells and antigen-pulsed antigen-presenting cells Ceased AU727863B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4594997P 1997-05-08 1997-05-08
US60/045949 1997-05-08
PCT/US1998/009288 WO1998050527A1 (en) 1997-05-08 1998-05-07 Method for generating activated t-cells and antigen-pulsed antigen-presenting cells

Publications (2)

Publication Number Publication Date
AU7371298A AU7371298A (en) 1998-11-27
AU727863B2 true AU727863B2 (en) 2001-01-04

Family

ID=21940709

Family Applications (1)

Application Number Title Priority Date Filing Date
AU73712/98A Ceased AU727863B2 (en) 1997-05-08 1998-05-07 Method for generating activated T-cells and antigen-pulsed antigen-presenting cells

Country Status (10)

Country Link
US (1) US6600012B1 (cg-RX-API-DMAC10.html)
EP (3) EP0986636B1 (cg-RX-API-DMAC10.html)
JP (1) JP4480800B2 (cg-RX-API-DMAC10.html)
AT (2) ATE394474T1 (cg-RX-API-DMAC10.html)
AU (1) AU727863B2 (cg-RX-API-DMAC10.html)
CA (1) CA2289742C (cg-RX-API-DMAC10.html)
DE (2) DE69839443D1 (cg-RX-API-DMAC10.html)
DK (1) DK1634949T3 (cg-RX-API-DMAC10.html)
ES (1) ES2357960T3 (cg-RX-API-DMAC10.html)
WO (1) WO1998050527A1 (cg-RX-API-DMAC10.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19906744A1 (de) * 1999-02-18 2000-08-24 Martin Roecken Verfahren zur Herstellung antitumoraler Th1-Zellen
CA2368967A1 (en) * 1999-04-09 2000-10-19 Biomira, Inc. Telomerase-specific cancer vaccine
DE19917195B4 (de) * 1999-04-16 2006-09-28 Immatics Biotechnologies Gmbh Peptid zur Auslösung einer Immunreaktion gegen Tumorzellen, diese enthaltende pharmzeutische Zusammensetzungen, dessen Verwendungen, dafür codierende Nukleinsäure und diese Nukleinsäure enthaltender Expressionsvektor
WO2001018035A2 (en) * 1999-09-08 2001-03-15 Transgene S.A. Muc-1 derived peptides
GB9921337D0 (en) 1999-09-09 1999-11-10 Axis Genetics Plc Modified plant viruses
GB0007150D0 (en) * 2000-03-24 2000-05-17 Lamellar Therapeutics Limited Immunotherapeutic methods and compositions
ES2424131T3 (es) * 2001-03-27 2013-09-27 Oncothyreon Inc. Vacuna para modular respuestas inmunitarias entre T1 y T2
US7282222B2 (en) 2002-03-15 2007-10-16 The United States Of America As Represented By The Department Of Veterans Affairs Methods and compositions for directing cells to target organs
EP1572918B1 (en) * 2002-04-15 2011-10-19 Oncothyreon Inc. Synthetic glyco-lipo-peptides as vaccines
US20060142546A1 (en) * 2002-09-05 2006-06-29 Franz-Georg Hanisch Immunogenic muc1 glycopeptides
CA2501527A1 (en) * 2002-10-10 2004-04-22 Catherine A. Phillips Detection, localization and staging of tumors using labeled activated lymphocytes directed to a tumor specific epitope
US20050045205A1 (en) * 2003-08-29 2005-03-03 Stach Steven R. Apparatus and method for cleaning printed circuit boards
GB0322448D0 (en) 2003-09-25 2003-10-29 Lamellar Therapeutics Ltd Using lamellar bodies to modify linear biological macro molecules
JP5060134B2 (ja) * 2003-12-12 2012-10-31 ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ・アズ リプレゼンテッド バイ ザ セクレタリー・デパートメント オブ ヘルス アンド ヒューマン サービシーズ ヒト細胞傷害性Tリンパ球のエピトープ及びそのMUC−1の非VNTR(non−variablenumberoftandemrepeatsequence)由来のアゴニストエピトープ
TW201204410A (en) 2004-04-01 2012-02-01 Oncothyreon Inc Mucinous glycoprotein (MUC-1) vaccine
EP1812052A1 (en) * 2004-11-02 2007-08-01 Biomedical Research Models, Inc. Methods of cancer treatment/prevention using cancer cell-specific surface antigens
PT2366400E (pt) 2005-06-28 2016-02-02 Oncothyreon Inc Método de tratamento de doentes com uma vacina à base de glicoproteína mucinosa (muc-1)
WO2010002478A2 (en) 2008-07-03 2010-01-07 University Of Georgia Research Foundation, Inc. Glycopeptide and uses thereof
CA2637600A1 (en) 2006-01-17 2007-07-26 Health Research, Inc. Heteroduplex tracking assay
RU2377994C1 (ru) * 2008-05-21 2010-01-10 Леонид Валентинович Загребин Способ иммунореабилитации онкозаболеваний
US20100059084A1 (en) * 2008-09-10 2010-03-11 Austin American Technology Corporation Cleaning and testing ionic cleanliness of electronic assemblies
RU2578420C2 (ru) 2010-05-10 2016-03-27 Эсенд Байофармасьютикалз Пти Лтд Иммуностимулирующие и вакцинные композиции
JP2014518841A (ja) 2011-02-24 2014-08-07 オンコシレオン インク. アジュバントを備えたmuc1ベースのグリコリポペプチドワクチン
WO2013103658A1 (en) 2012-01-03 2013-07-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Native and agonist ctl epitopes of the muc1 tumor antigen
JP2016520073A (ja) 2013-05-14 2016-07-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung Muc−1リポペプチドによるワクチン免疫で肺癌を治療する方法
WO2015058831A1 (en) 2013-10-25 2015-04-30 Merck Patent Gmbh Elevated biomarker expression in lung cancer patients responding to treatment with muc-1 lipopeptide vaccines
CN110325205B (zh) 2016-12-22 2023-08-15 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
US11851471B2 (en) 2017-01-09 2023-12-26 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
KR20240005989A (ko) 2017-03-15 2024-01-12 큐 바이오파마, 인크. 면역 반응을 조절하는 방법
GB201812647D0 (en) 2018-08-03 2018-09-19 Chancellor Masters And Scholars Of The Univ Of Oxford Viral vectors and methods for the prevention or treatment of cancer
JP2022536581A (ja) * 2019-06-19 2022-08-18 キュー バイオファーマ, インコーポレイテッド 多量体t細胞調節性ポリペプチド及びその使用方法
IL296209A (en) 2020-05-12 2022-11-01 Cue Biopharma Inc Multimeric t-cell modulatory polypeptides and methods of using them
JP2023541366A (ja) 2020-09-09 2023-10-02 キュー バイオファーマ, インコーポレイテッド 1型真性糖尿病(t1d)を治療するためのmhcクラスii t細胞調節多量体ポリペプチド及びその使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2135068T3 (es) 1994-06-13 1999-10-16 Unilever Nv Activacion de blanqueantes.
DK0765386T3 (en) * 1994-06-14 2015-01-26 Univ Leland Stanford Junior Methods for T cell activation in vivo with antigen-incubated dendritic cells
AU5849796A (en) * 1994-12-27 1996-08-07 United Biomedical Inc. Peptide ratchet libraries for ctl-inducing vaccines and therapeutics
AU6330896A (en) * 1995-06-07 1996-12-30 Governors Of The University Of Alberta, The A method for eliciting a th1-specific immune response
CA2282300C (en) 1997-02-24 2011-08-02 Therion Biologics Corporation Recombinant pox virus for immunization against muc1 tumor-associated antigen

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AGRAWAL ET AL, JOURNAL OF IMMUNOLOGY, 1996, 157:2089-2095 *
GAGLIARDI ET AL, INTERNATIONAL IMMUNOLOGY,'95,7(11):1741-52 *

Also Published As

Publication number Publication date
US6600012B1 (en) 2003-07-29
EP1634949B1 (en) 2010-12-15
CA2289742C (en) 2013-07-16
JP2001525668A (ja) 2001-12-11
JP4480800B2 (ja) 2010-06-16
EP0986636B1 (en) 2008-05-07
ATE394474T1 (de) 2008-05-15
AU7371298A (en) 1998-11-27
EP1634949A1 (en) 2006-03-15
DE69842060D1 (de) 2011-01-27
ES2357960T3 (es) 2011-05-04
WO1998050527A1 (en) 1998-11-12
EP2341072A2 (en) 2011-07-06
CA2289742A1 (en) 1998-11-12
EP2341072A3 (en) 2013-10-30
DK1634949T3 (da) 2011-03-28
DE69839443D1 (de) 2008-06-19
EP0986636A1 (en) 2000-03-22
ATE491465T1 (de) 2011-01-15

Similar Documents

Publication Publication Date Title
EP0986636B1 (en) Method for generating activated t-cells and antigen-pulsed antigen-presenting cells
Reddish et al. Anti‐MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide
Corr et al. Costimulation provided by DNA immunization enhances antitumor immunity
US6077519A (en) Methods for isolation and use of T cell epitopes eluted from viable cells in vaccines for treating cancer patients
TW514530B (en) Tumor vaccines and methods for their production
US8552145B2 (en) Vaccine for modulating between T1 and T2 immune responses
Agrawal et al. Rapid induction of primary human CD4+ and CD8+ T cell responses against cancer-associated MUC1 peptide epitopes.
Hermans et al. Tumor-peptide-pulsed dendritic cells isolated from spleen or cultured in vitro from bone marrow precursors can provide protection against tumor challenge
AU4825700A (en) Use of soluble costimulatory molecules to enhance immune responses
AU781376B2 (en) Telomerase-specific cancer vaccine
JP4592702B2 (ja) NY−ESO−1とアジュバントのinvivo有効性
AU2002309141A1 (en) Vaccine for modulating between T1 and T2 immune responses
US20020018806A1 (en) Lipopeptide adjuvants
KR20030070454A (ko) 면역 치료용 성숙화된 수지상 세포 백신의 제조방법
EP1852126B1 (en) Vaccine for modulating between T1 and T2 immune responses
AU4111999A (en) Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes